Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 18;21(5):391. doi: 10.3892/ol.2021.12652

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Cao et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 1. — BMPR2 expression levels in different types of human cancer. (A) Abnormal expression of BMPR2 in data sets of different cancer types compared with normal tissues in the Oncomine database. (B) BMPR2 expression was higher in osteosarcoma (14 samples) compared with in normal tissues (four samples). BMPR2 expression level was higher in AMRS (15 samples) and ERMS (15 samples) compared with in the normal tissues (26 samples). (C) BMPR2 expression was significantly higher in metastatic osteosarcomas than in non-metastatic osteosarcomas. BMPR2 expression was significantly higher in sarcomas that did not respond well to chemotherapy compared with in those that did. (D) High expression level of BMPR2 was associated with worse OS and metastasis-free OS. (E) AUC values for the expression level of BMPR2 in predicting metastatic and 5-year survival. (F) High expression level of BMPR2 was associated with worse OS. ARMS, acinar rhabdomyosarcoma; ERMS, embryonal rhabdomyosarcoma; BMPR2, bone morphogenetic protein receptor 2; OS, overall survival; AUC, area under the curve.